PACE AS TREATMENT OF RESCUE IN PATIENTS WITH MULTIPLE RELAPSED OR REFRACTORY MYELOMA

被引：0
|
作者：
Isola, I. [1 ]
Granell, M. [2 ]
Marti Josep, M. [3 ]
Gironella, M. [4 ]
Garcia-Guinon, A. [5 ]
Lopez-Pardo, J. [2 ]
Muntanola, A. [3 ]
Abella, E. [6 ]
Motllo, C. [7 ]
Escoda, L. [8 ]
Sierra, J. [2 ]
Blade, J. [1 ]
Rosinol, L. [1 ]
Fernandez de larrea, C. [1 ]
机构：
[1] Hosp Clin Barcelona, Serv Hematol, Unidad Amiloidosis & Mieloma, IDIBAPS, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Serv Hematol, Barcelona, Spain
[3] Hosp Mutua Terrassa, Serv Hematol, Terrassa, Spain
[4] Hosp Valle De Hebron, Serv Hematol, Barcelona, Spain
[5] Hosp Arnau Vilanova, Serv Hematol, Lleida, Spain
[6] Hosp del Mar, Serv Hematol, Barcelona, Spain
[7] Hosp Badalona Germans Trias & Pujol, Serv Hematol, Badalona, Spain
[8] Hosp Joan 23, Serv Hematol, Tarragona, Spain
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-070
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [31] Management of patients with relapsed/refractory multiple myeloma
    Ludwig, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 3 - 4
  • [32] A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
    Cook, Gordon
    Zweegman, Sonja
    Mateos, Maria-Victoria
    Suzan, Florence
    Moreau, Philippe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 121 : 74 - 89
  • [33] Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
    Janet A. Parsons
    Nicole R. Greenspan
    Natalie A. Baker
    Chris McKillop
    Lisa K. Hicks
    Olivia Chan
    BMC Cancer, 19
  • [34] Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
    Ailawadhi, Sikander
    Dersarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert
    CLINICAL THERAPEUTICS, 2019, 41 (03) : 477 - 493
  • [35] Targeted Therapy Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    ONCOLOGY-NEW YORK, 2021, 35 (05): : 284 - 287
  • [36] Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients
    Mangiacavalli, Silvia
    Pica, GianMatteo
    Varettoni, Marzia
    Lazzarino, Mario
    Corso, Alessandro
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (03) : 240 - 241
  • [37] The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma
    Andreu-Vieyra, Claudia V.
    Berenson, James R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (06) : 197 - 210
  • [38] Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
    Le Ray, Emmanuelle
    Jagannath, Sundar
    Palumbo, Antonio
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (01) : 91 - 105
  • [39] RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: TREATMENT OPTIONS AND POSSIBLE SEQUENCES
    Bringhen, S.
    Mina, R.
    Boccadoro, M.
    HAEMATOLOGICA, 2017, 102 : 177 - 180
  • [40] Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Dimopoulos, Meletios-Athanasios
    Richardson, Paul
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 460 - 473
12345